Compare Chevron Corp (CVX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Chevron Corp trades at $209.46 (market cap $402.42B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Chevron Corp is far larger — about 3.1× Vertex Pharmaceuticals Incorporated's market cap, and Chevron Corp pays a 3.47% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CVX | VRTX | |
|---|---|---|
Market Cap | $402.42B | $128.16B |
Volume | 5,699,721 | 806,603 |
Sector | Energy | Health |
52-Week High | $217.73 | $557.96 |
52-Week Low | $146.72 | $407.37 |
Typical Hold Time | 101 Days | 120 Days |
Enterprise Value | $430.97B | $122.29B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 1.92% today, with a neutral technical signal. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 estimate. Revenue for 2025 was $184.43B, though net income declined to $12.30B. Analyst consensus is bullish with a $208.31 price target and 62% buy ratings. Recent news highlights Chevron's $13.8B investment in Argentina's Vaca Muerta and geopolitical impacts on oil prices.
The outlook for CVX is supported by high oil prices and strategic investments, but risks include volatile energy markets and declining profit margins. Earnings growth and dividend stability remain key catalysts, though geopolitical tensions and operational execution pose challenges for sustained shareholder returns.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
